A Trade Agreement's Impact On Access To Generic Drugs
- 1 January 2009
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 28 (Supplement) , w957-w968
Abstract
Millions of people lack access to affordable medicines. The intellectual property rules in the Central America Free Trade Agreement (CAFTA) provide pharmaceutical companies with monopoly protections that allow them to market some drugs without competition by less costly generics. We examined availability of certain drugs in Guatemala and found that CAFTA intellectual property rules reduced access to some generic drugs already on the market and delayed new entry of other generics. Some drugs protected from competition in Guatemala will become open for generic competition in the United States before generic versions will be legally available in Guatemala.Keywords
This publication has 2 references indexed in Scilit:
- Eliminating Neglected Diseases In Poor Countries: A Conversation With Andrew WittyHealth Affairs, 2009
- Public health-friendly options for protecting pharmaceutical registration dataInternational Journal of Intellectual Property Management, 2006